386 related articles for article (PubMed ID: 15161435)
41. Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.
Woods B; Paracha N; Scott DA; Thatcher N
Lung Cancer; 2012 Feb; 75(2):261-7. PubMed ID: 21937141
[TBL] [Abstract][Full Text] [Related]
42. Chemotherapy for malignant pleural mesothelioma: past results and recent developments.
Tomek S; Manegold C
Lung Cancer; 2004 Aug; 45 Suppl 1():S103-19. PubMed ID: 15261443
[TBL] [Abstract][Full Text] [Related]
43. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
Santoro A; O'Brien ME; Stahel RA; Nackaerts K; Baas P; Karthaus M; Eberhardt W; Paz-Ares L; Sundstrom S; Liu Y; Ripoche V; Blatter J; Visseren-Grul CM; Manegold C
J Thorac Oncol; 2008 Jul; 3(7):756-63. PubMed ID: 18594322
[TBL] [Abstract][Full Text] [Related]
44. Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia.
Hasani A; Feeney K; Nowak A; Millward M
Asia Pac J Clin Oncol; 2010 Dec; 6(4):350-6. PubMed ID: 21114785
[TBL] [Abstract][Full Text] [Related]
45. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy.
Villela LR; Stanford BL; Shah SR
Pharmacotherapy; 2006 May; 26(5):641-54. PubMed ID: 16637794
[TBL] [Abstract][Full Text] [Related]
46. [First-line treatment with pemetrexed in association with cisplatin in patients with non-operable malignant pleural mesothelioma].
Burgin M; Gairard-Dory A-; Mennecier B; Molard A; Beretz L; Quoix A-
Rev Pneumol Clin; 2009 Apr; 65(2):75-83. PubMed ID: 19375046
[TBL] [Abstract][Full Text] [Related]
47. [Expanded access program in the United States and Alimta program for malignant mesothelioma patients].
Nambu Y
Gan To Kagaku Ryoho; 2007 Feb; 34(2):284-6. PubMed ID: 17301544
[TBL] [Abstract][Full Text] [Related]
48. Pemetrexed (Alimta) for mesothelioma.
Med Lett Drugs Ther; 2004 Apr; 46(1180):31-2. PubMed ID: 15079145
[No Abstract] [Full Text] [Related]
49. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
Taylor P; Castagneto B; Dark G; Marangolo M; Scagliotti GV; van Klaveren RJ; Labianca R; Serke M; Schuette W; van Meerbeeck JP; Heigener D; Liu Y; Adachi S; Blatter J; von Pawel J
J Thorac Oncol; 2008 Jul; 3(7):764-71. PubMed ID: 18594323
[TBL] [Abstract][Full Text] [Related]
50. A retrospective study of chemotherapy with and without pemetrexed in malignant pleural mesothelioma.
Higashiguchi M; Suzuki H; Hirashima T; Kobayashi M; Goya S; Okamoto N; Matsuura Y; Tamiya M; Morishita N; Tsumori T; Kawase I
Anticancer Res; 2012 Feb; 32(2):609-13. PubMed ID: 22287752
[TBL] [Abstract][Full Text] [Related]
51. Pemetrexed disodium (Eli Lilly).
Norman P
Curr Opin Investig Drugs; 2001 Nov; 2(11):1611-22. PubMed ID: 11763166
[TBL] [Abstract][Full Text] [Related]
52. Malignant pleural mesothelioma: current treatments and emerging drugs.
Belli C; Fennell D; Giovannini M; Gaudino G; Mutti L
Expert Opin Emerg Drugs; 2009 Sep; 14(3):423-37. PubMed ID: 19552609
[TBL] [Abstract][Full Text] [Related]
53. Need for further information on pemetrexed study.
Aelony Y
J Clin Oncol; 2004 Oct; 22(20):4234-5; author reply 4235-6. PubMed ID: 15483040
[No Abstract] [Full Text] [Related]
54. Raltitrexed and pemetrexed studies in mesothelioma have not shown improved quality of life nor prolonged survival compared with effective pleurodesis with thoracoscopic talc poudrage.
Aelony Y
J Clin Oncol; 2006 Oct; 24(28):4667; author reply 4667-8. PubMed ID: 17008709
[No Abstract] [Full Text] [Related]
55. Can pemetrexed help in malignant mesothelioma?
Drug Ther Bull; 2006 Oct; 44(10):77-80. PubMed ID: 17067119
[TBL] [Abstract][Full Text] [Related]
56. Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.
Mairinger F; Vollbrecht C; Halbwedl I; Hatz M; Stacher E; Gülly C; Quehenberger F; Stephan-Falkenau S; Kollmeier J; Roth A; Mairinger T; Popper H
J Thorac Oncol; 2013 May; 8(5):644-53. PubMed ID: 23449276
[TBL] [Abstract][Full Text] [Related]
57. Pemetrexed in malignant pleural mesothelioma and the clinical outcome.
Knuuttila A; Salomaa ER; Saikkonen S; Hurme S; Salo J
Clin Respir J; 2012 Apr; 6(2):96-103. PubMed ID: 21651743
[TBL] [Abstract][Full Text] [Related]
58. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
[TBL] [Abstract][Full Text] [Related]
59. The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer.
Le Chevalier T
Semin Oncol; 2003 Aug; 30(4 Suppl 10):37-44. PubMed ID: 12947960
[TBL] [Abstract][Full Text] [Related]
60. [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
Reck M; Heigener DF; Gatzemeier U
Zentralbl Chir; 2008 Jun; 133(3):238-42. PubMed ID: 18563688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
